During spring 2005, two tetanus toxoid, reduced diphtheria toxoid and acellular pertussis
vaccine (Tdap) products formulated for use in adolescents (and, for one product, use in …

Summary On June 10, 2005, a tetanus toxoid, reduced diphtheria toxoid and acellular
pertussis vaccine (Tdap) formulated for use in adults and adolescents was licensed in the …

This report compiles and summarizes all recommendations from CDC's Advisory Committee
on Immunization Practices (ACIP) regarding prevention and control of tetanus, diphtheria …

Despite sustained high coverage for childhood pertussis vaccination, pertussis remains
poorly controlled in the United States. A total of 16,858 pertussis cases and 12 infant deaths …

Background. Pertussis is among the most poorly controlled bacterial vaccine-preventable
diseases in the United States. In 2006, a tetanus, reduced-dose diphtheria, and acellular …

Background. We estimated the vaccine effectiveness (VE) of tetanus-diphtheria-acellular
pertussis vaccine (Tdap) for preventing pertussis among adolescents during a statewide …

In 2005, two tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap)
vaccines were licensed and recommended for use in adults and adolescents in the United …

Background: Adult formulation tetanus and diphtheria toxoids and acellular pertussis
vaccines (Tdap) have been developed to prevent pertussis in adolescents and adults. There …

ContextIncreasing reports of pertussis among US adolescents, adults, and their infant
contacts have stimulated vaccine development for older age groups. ObjectiveTo assess the …

Compared with older children and adults, infants aged < 12 months have substantially
higher rates of pertussis and the largest burden of pertussis-related deaths. Since 2004, a …